Rimonabant Hydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I002014
  • CAS Number: 158681-13-1
  • Molecular Formula: C22H22Cl4N4O
  • Molecular Weight: 500.25
  • Purity: ≥95%
Inquiry Now

Rimonabant Hydrochloride(Cat No.:I002014)is a selective cannabinoid receptor type 1 (CB1) antagonist that was developed for the treatment of obesity and metabolic disorders. By blocking CB1 receptors in the brain, it reduces appetite and promotes weight loss. Additionally, Rimonabant has been investigated for its effects on improving lipid profiles and insulin sensitivity, offering potential benefits for managing type 2 diabetes and cardiovascular risk factors. However, due to concerns over psychiatric side effects, such as depression and anxiety, its use was discontinued, but it remains a subject of interest in cannabinoid receptor research.


Catalog Number I002014
CAS Number 158681-13-1
Synonyms

5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide;hydrochloride

Molecular Formula C22H22Cl4N4O
Purity ≥95%
Target Cannabinoid Receptor
Solubility in DMSO> 10 mM
Storage Store at -20°C
IC50 1.8 nM(Ki)
IUPAC Name 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide;hydrochloride
InChI InChI=1S/C22H21Cl3N4O.ClH/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15;/h5-10,13H,2-4,11-12H2,1H3,(H,27,30);1H
InChIKey REOYOKXLUFHOBV-UHFFFAOYSA-N
SMILES CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl.Cl
Reference

<p style=/line-height:25px/>
<br>[1]. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D/’Esposito V, Beguinot F, Formisano P, Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol. 2008 Dec;74(6):1678-86.
<br>[2]. Cox SL. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Drugs Today (Barc). 2005 Aug;41(8):499-508.
<br>[3]. Beardsley PM, Martin BR. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal. Eur J Pharmacol. 2000 Jan 3;387(1):47-53.
<br>[4]. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther. 1998 Aug;286(2):697-703.
<br>[5]. Shivachar AC, Martin BR, Ellis EF. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochem Pharmacol. 1996 Mar 8;51(5):669-76.
</p>

Request a Quote